应用蛋白质芯片技术从血清中筛选肺癌标志蛋白

探讨用蛋白质芯片技术筛选肺癌病人血清中的特异性标志蛋白. 采用SELDI (surfaced enhanced laser desorption/ionization)蛋白芯片技术检测了30例肺癌(15例原发癌, 9例转移癌, 6例化疗后)病人血清和12例正常人血清中的蛋白质谱. 选用阴离子交换柱处理血清样品, 用5个不同pH的洗脱液和有机溶剂洗脱柱床, 通过改变洗脱液的pH值得到6个具有不同pI的蛋白质组分. 每个组分用IMAC-Cu和WCX2两种芯片检测. 采用美国Ciphergen 生物公司研制的蛋白质芯片阅读机读取数据, 获得的蛋白质谱采用Ciphergen 公司的Biomark Wizard软件分析. 结果显示, 肺癌病人与正常人的血清中有15个差异蛋白(标志分子)表达. 与正常人血清相比, 6个蛋白质在肺癌病人血清中高表达, 9个蛋白质在肺癌病人血清中低表达. 采用单一标志分子检测时, 敏感性为44.82%~93.1%, 特异性为85%~94.4%. 其中5个标志分子在两种芯片上被检测出来. 实验证明与肺癌相关的特异性标志分子可从病人血清中检测出来, 而且蛋白质芯片技术对于发现和筛选血清中的肺癌标志蛋白是一种有效、快速的工具.     

Proteomic approaches to biomarker discovery in lung cancers by SELDI technology

Lung cancer is one of the most common tumors all over the world and one of those with higher mortality in clinic. For instance, 169500 new cases of lung cancer were estimated in the United States for 2001[1]. In recent years, both morbidity and mortality of lung cancer were reported gradually increasing in our country. Therefore, it has become an urgent task to search and discover specific biomarkers for lung cancer. In tumor genesis, certain cellular proteins must have changed their express…     

Proteomic approaches to biomarker discovery in lung cancers by SELDI technology

The purpose of the present work is to identify protein profiles that could be used to discover specific biomarkers in serum and discriminate lung cancer. Thirty serum samples from patients with lung cancer (15 cases of primary brochogenic carcinoma, 9 cases of metastasis lung cancer and 6 cases of lung cancer after chemotherapy) and twelve from healthy individuals were analyzed by SELDI (Surfaced Enhanced Laser Desorption/Ionization) technology. Anion-exchange columns were used to fractionate the sera with 6 designated pH washing solutions. Two types of protein chip arrays, IMAC-Cu and WCX2, were employed. Protein chips were examined in PBSII ProteinChip Reader (Ciphergen Biosystems Inc.) and the resulting profiles between cancer and normal were analyzed with Biomarker Wizard System. In total, 15 potential lung cancer biomarkers, of which 6 were up-regulated and 9 were down-regulated, were discovered in the serum samples from patients with lung cancer. 5 of 15 these biomarkers were able to be detected on both WCX2 and IMAC-Cu protein chips. The sensitivities provided by the individual markers range from 44.8% to 93.1% and the specificities were 85.0%–94.4%. Our results suggest that serum is a capable resource for detection of lung cancer with specific biomarkers. Moreover, protein chip array system was shown to be a useful tool for identification, as well as detection of disease biomarkers in sera.